Key result
Bazedoxifene attenuates cardiac fibroblast activation and fibrosis by inhibiting the IL-6/STAT3 signaling axis.
Why the study?
The direct effects of bazedoxifene on cardiac fibroblasts and its underlying mechanisms remain unclear.
p-value: p=<0.05
Bazedoxifene attenuates isoproterenol-induced cardiac fibroblast activation and fibrotic phenotype in vitro by inhibiting the IL-6/STAT3 signaling pathway, highlighting its potential as a candidate anti-myocardial fibrosis agent.
Bazedoxifene may inhibit cardiac fibroblast activation in vitro; hypothesis-generating for IL-6/STAT3-targeted anti-fibrotic therapy but requires in vivo validation.
Bazedoxifene (BAZ), a selective estrogen receptor modulator, has recently been demonstrated to inhibit the IL-6/STAT3 signaling pathway; however, its direct effects on cardiac fibroblasts and the underlying mechanisms remain unclear. Isoproterenol (ISO)-stimulated Sprague–Dawley neonatal rat cardiac fibroblasts (CFs) were employed as an in vitro model. CCK-8 assay, flow cytometry, Transwell migration assay, ELISA, qRT-PCR, and Western blot were applied to evaluate the effects of BAZ on CF activation, proliferation, migration, and collagen synthesis. Additionally, IL-6 overexpression via lentivirus (Lv-IL-6) was used to assess mediation by IL-6/STAT3 signaling. BAZ (5 μmol/L) significantly inhibited ISO-induced CF proliferation by inducing G0/G1 cell-cycle arrest; migration and upregulation of α-SMA and Collagen I/III were reduced; IL-6, TGF-β1, and hydroxyproline concentrations in the conditioned medium were decreased; STAT3 phosphorylation was significantly suppressed. Supplementation with Lv-IL-6 partially reversed these effects. The suppression of ISO-induced CF activation and fibrotic phenotype was associated with inhibition of IL-6 expression and blockade of IL-6/STAT3 signaling, suggesting the involvement of this pathway in the anti-fibrotic effects of BAZ. These findings provide in vitro evidence supporting BAZ as a candidate anti-myocardial fibrosis agent.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied Myocardial fibrosis. Bazedoxifene vs. Isoproterenol (ISO) alone was evaluated on Cardiac fibroblast activation, proliferation, migration, and collagen synthesis (p=<0.05). Bazedoxifene significantly attenuated isoproterenol-induced cardiac fibroblast activation and fibrotic phenotype by inhibiting the IL-6/STAT3 signaling axis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: